GlassScriptPhysician profile
Nivin C Todd
NPI 1356390579
$1,536.00
in general payments reported to CMS, 2019-2025
14 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.50 · 2021: $28.99 · 2022: $138 · 2023: $538 · 2024: $548 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.96 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $429.86 | 2023-2024 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $312.66 | 2023-2025 | Veozah, Vesicare |
| Amgen INC. | $138.69 | 2023-2025 | Evenity, Prolia |
| Lilly USA, LLC | $130.27 | 2024-2025 | Zepbound |
| Sage Therapeutics, LLC | $98.00 | 2023-2025 | Zurzuvae |
| Pfizer INC. | $84.50 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $77.97 | 2021-2023 | |
| Abbvie INC. | $59.12 | 2023 | Lo Loestrin Fe, Orilissa |
| Myovant Sciences INC. | $58.46 | 2021-2022 | |
| Coloplast Corp | $38.58 | 2024 | |
| Shield Therapeutics INC | $35.29 | 2023-2024 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $34.13 | 2022 | |
| Roche Diagnostics Corporation | $23.50 | 2019 | |
| Boston Scientific Corporation | $14.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nivin Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.